Highlights

  • 09 May 2017
    - Highlights

    What pricing and reimbursement policies to use for off-patent biologicals? – Results from the second EBE biological medicines policy survey

    Objective: Biosimilar policies with a focus on uptake have received a lot of attention at national and regional level in the last few years. It is now 10 years since the first biosimilar was approved in the European Union, but do policies in the Member States take the differences between biological medicines and small-molecule generics into account? To map the policy landscape in Europe, European Biopharmaceutical Enterprises (EBE) has conducted a second round of its descriptive survey of pricing and reimbursement policies for off-patent biologicals.
    Read more |
  • 28 Apr 2017
    - Highlights

    Podcast: EBE Plots Path from “Flawed Underfunded Biotech System”

    During DIA’s first DIA BioVenture Day, EBE Executive Director Barbara Freischem delivered a presentation titled Europe’s Flawed and Underfunded Biotech System, which she explores in this exclusive Global Forum podcast.

    Read more |
  • 05 Apr 2017
    - Highlights

    Podcast: How To Support Advanced Therapies and Breakthrough Medicines in Europe

    On the occasion of  the first DIA BioVenture day on 28 March 2017 in Glasgow, Menno Aarnout, Wolfgang Stoiber and EBE's Barbara Freischem discussed options for solutions to support the development and funding of Advanced Therapies and Breakthrough Medicines in Europe.

    Read more |
  • 31 Mar 2017
    - Highlights

    Open Call to all ATMP developers

    Invitation for ATMP-developers to help improve product development and its regulation 

    Advanced Therapy Medicinal Products (ATMPs) are medicinal products including gene therapies, somatic cell therapies and tissue engineered products. They are characterised by their innovative character, frequently addressing disease with high unmet medical need. Despite considerable development activity in this dynamic field, a limited number of ATMPs have received Market Authorisation in the European Union. There is a growing urgency to understand which factors are associated with the advancement of ATMPs through the medicines life-cycle.

    Read more |